Aclaris Therapeutics Files 8-K

Ticker: ACRS · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1557746

Aclaris Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAclaris Therapeutics, INC. (ACRS)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

Related Tickers: ACRS

TL;DR

ACRS filed a routine 8-K, no major news.

AI Summary

Aclaris Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on Regulation FD disclosures and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing serves as a routine update for investors, indicating that Aclaris Therapeutics, Inc. is meeting its disclosure obligations with the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting purposes and does not disclose any new material events or financial information that would indicate increased risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Aclaris Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to include financial statements and exhibits as required by the SEC.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is January 13, 2025.

What is the state of incorporation for Aclaris Therapeutics, Inc.?

Aclaris Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Aclaris Therapeutics, Inc.?

The principal executive office address is 701 Lee Road, Suite 103, Wayne, PA 19087.

Does this 8-K filing announce any new material events or financial results?

Based on the provided text, this 8-K filing appears to be a routine report and does not explicitly announce any new material events or specific financial results beyond the standard reporting requirements.

Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-13 07:00:16

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, Aclaris Therapeutics, Inc. (the " Company ") updated its corporate overview presentation, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The updated corporate overview presentation is also available on the Company's website. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Company Presentation. 104 The cover page from Aclaris Therapeutics, Inc.'s Form 8-K filed on January 13, 2025, formatted in Inline XBRL. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARIS THERAPEUTICS, INC. By: /s/ Kevin Balthaser Date: January 13, 2025 Kevin Balthaser Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing